KLS:7148

Duopharma Biotech Berhad · KLS · Healthcare · MYR · FY for 2025

Figures on this page computed 2026-11-08 12:26 UTC

Last close

n/aMYR

Market data

12.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
9.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
9.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
3.1%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

All from 100

lens 2 of 9

Sales

298

2016-12-31 to 2025-12-31100 at the start298

Sales: 100.00 on 2016-12-31 to 297.72 on 2025-12-31, up 198%.

Profit

326

2016-12-31 to 2025-12-31100 at the start326

Profit: 100.00 on 2016-12-31 to 326.04 on 2025-12-31, up 226%.

Shares in issue

111

2016-12-31 to 2025-12-31100 at the start111

Shares in issue: 100.00 on 2016-12-31 to 110.84 on 2025-12-31, up 11%.

Sales is at 298, Profit is at 326, Shares in issue is at 111, against 100 in 2016.

Sales is at 298, Profit is at 326, Shares in issue is at 111, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100298
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Profit, where the first year is 100326
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Shares in issue, where the first year is 100111
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR